Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The protein expressed by the ABCB11 (ATP binding cassette, sub-family B member 11) gene is also called a bile salt export pump (BESP). The ABCB11 gene belongs to the ATP binding cassette (ABC) transporter family, which is mainly expressed in the liver tissue. Its two transmembrane domains (TMD) and two nucleotide domains (NBD) constitute a classical ABC transporter.
ABCB11 is a special glycoprotein in the liver. By the consumption of ATP, hepatic bile duct cells secrete bile salts in hepatocytes into the bile duct to form bile. In this process, BESP plays a vital role. The encoded expression of the ABCB11 gene is highly regulated by the farnesoid X receptor (FXR) and the retinoid X receptor α-heterodimer (RXR). FXR is an important transcription factor regulated by bile acids, and the synthesis and transport of bile acids are regulated by it. BESP is recruited to the vesicle apical membrane of hepatocytes and binds to pathways that have cAMP and regulate PI3K signaling, thereby reducing intracellular osmotic pressure leading to hepatocyte swelling and bile acid secretion. BESP is mainly involved in the delivery of monovalent bile salts, including bile acids (CA) and chenodeoxycholic acid (CDCA), secondary bile acid deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA).
Abnormal Expression of ABCB11 Gene Forms Cholestasis
Changes in the ABCB11 gene directly affect its protein expression and function and are associated with a variety of cholestatic liver and gallbladder diseases. Human genome sequencing revealed familial intrahepatic cholestasis caused by abnormal expression of the ABCB11 gene. It usually occurs in infancy and is called progressive familial intrahepatic cholestasis type II (PFIC2), an autosomal recessive genetic disorder. This finding confirms that BESP is identified as a determinant of bile salt-dependent bile flow. Additional mutations and polymorphisms in ABCB11 were also found to indicate that significant changes in the ABCB11 gene result in altered function of the BESP leading to liver disease. This series of mild to severe lesions gradually formed a cholestasis called the BESP deficiency syndrome.
Other studies have also suggested that the clinical pathological changes of PFIC2 characterized by low glutamate transpeptidase (GGT) are associated with genetic changes in hepatocytes ABCB11 and ATP8B1. A lesion similar to PFIC2 is called benign recurrent intrahepatic cholestasis (BRIC2), which is a slightly stable disease and is an autosomal recessive genetic disorder that can occur at any age. The main clinical manifestations are recurrent episodes of jaundice and itching. The course of disease can last for several weeks and can be relieved by itself, but it can develop into PFIC2 after severe disease. At the same time, some scholars have also proposed that the clinical pathological changes of PFIC2 characterized by low glutamate transpeptidase (GGT) are related to the genetic changes of hepatocytes ABCB11 and ATP8B1. Lai et al. found that there are other types of cholestasis in the clinic. For example, cholestasis during pregnancy is also closely related to changes in ABCB11 gene expression, suggesting that this acquired physiological factor during pregnancy may inhibit the function of BESP and cause cholestasis.
Figure 1. The role of ABCB11 and BSEP in cholestasis. (Erlinger. 2015).
Hirobejahn et al. found that the ABCB11 gene plays a crucial role in the formation of bile acids and the metabolism of bile acids. And it is regulated by the FXR gene. Once the FXR changes, it will cause changes in cholestasis and bile acid. The change of the ratio of bile salts will reduce the dissolution of cholesterol and lead to the precipitation of cholesterol. This is an important risk factor for the formation of gallstones. It can be seen that changes in the ABCB11 gene cause intrahepatic bile duct cholestasis, which is bound to change bile acid composition, thus forming favorable conditions for gallstones.
ABCB11 Gene Alteration is A Direct Factor in Gallstone Formation
The study found that the bile salt export pump gene ABCB11 gene maps to the Light1 locus. Moreover, during the experiment, the overexpression of mouse BESP revealed that the cholesterol absorption of the mice increased and the cholesterol crystals increased in the bile, which greatly increased the probability of gallstone cholesterol stones. This study strongly supports ABCB11 as a gene that causes stones. The main role of ABCB11 protein is to participate in the secretion of bile. However, high expression of mice promotes the formation of food-borne obesity and hypercholesterolemia because of increased intestinal cholesterol absorption of hydrophobic bile acids and increased absorption of intestinal fat. Therefore, this ABCB11 gene overexpresses a series of expression processes to create a basis for the accelerated formation of gallstone cholesterol stones.
Kong et al. found that the relationship between BESP and PKCα and HAX-1 in the C57L mice fed a high cholesterol diet and on the hepatic tubular membrane was found to be related to the down-regulation of BESP expression. The interaction between BESP and HAX-1 has also increased. In a clinical statistical study, Condat et al. found that more than half of patients with cholelithiasis who did not exceed 18 years of age provided ABCB11 gene abnormalities. Some researchers have suggested that bile pigment stones have a certain correlation with ABCB11 and ABCC2 genes on hepatic bile ducts. The transport protein of the hepatic bile duct lateral membrane changes the bile secretion function and promotes the bile pigmentation. However, some scholars have studied the overexpression of mouse ABCB11 gene and found that excessive ABCB11 gene expression significantly promoted the increase of bile salts and circulating bile flow, while cholesterol and phospholipid secretion and gallbladder size and contraction were similar to the control group. The study suggests that the ABCB11 gene may not have much effect on cholesterol stones, and the results of this study have not been verified.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.